Pacira | PCRX - Debt


Pacira reported $367.66M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Assertio Holdings USD 38.87M 615K Sep/2023
Astellas Pharma JPY 831.43B 83.94B Mar/2025
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 47.93B 2.14B Dec/2025
Ligand Pharmaceuticals USD 451.49M 494K Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Omeros USD 442.16M 199K Sep/2023
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.64B 4.5M Dec/2025
Pfizer USD 63.73B 231M Mar/2026
Supernus Pharmaceuticals USD 40.98M 1.23M Dec/2025
Teva Pharmaceutical Industries USD 17.09B 21M Dec/2025
Xeris Pharmaceuticals USD 257.65M 431K Sep/2025
Xoma USD 120.79M 3.27M Jun/2024
Zoetis USD 9.24B 1.96B Dec/2025